Treatments | Optimist

advocatING for COVID-19 treatmentS

OPTIMIST advocates for the early treatment of COVID-19 as well as treatments for the after effects of the spike protein contracted either through COVID or COVID vaccination.

ministry of health & wellness protocols

The Ministry of Health & Wellness has a very limited outpatient protocol for early treatment, which is "Stay at home except to get medical care".

EARLY TREATMENTS FOR COVID-19

There are several documented early treatment protocols that were utilised by OPTIMIST Doctors to prevent severe disease, hospitalisation and death in patients during the pandemic.

Please refer to our disclaimer here

McCullough Protocol

Acute COVID-19 has a great range of clinical severity from asymptomatic to fatal.

In the absence of clinical trials and guidelines, and with hospitalizations and mortality mounting, we must deploy treatment for COVID-19 based on pathophysiological principles.

As a result, Dr. McCullough developed a renowned protocol based on age and co-morbidities that allows for many people to be monitored and treated at home during self-isolation -- reducing the risks of hospitalization and death.

Zelenko Protocol

In March 2020, Dr. Zelenko’s team was one of the first in the country to successfully treat thousands of Covid-19 patients in the prehospital setting utilising the Zelenko Protocol.

Dr. Zelenko wrote that "it is essential to start treatment against Covid-19 immediately upon clinical diagnosis of the infection and not to wait for confirmatory testing. There is a very narrow window of opportunity to eliminate the virus before pulmonary complications begin. Delaying treatment is the essence of the problem. My treatment regime ... has saved thousands of patients without serious complications or negative side effects."

He produces a range of supplements here.

Screenshot 2024-01-25 at 6.34_edited.jpg

Fareed Tyson Protocol

The following is the protocol Drs. Fareed and Tyson have jointly developed as most effective for their COVID-19 patients.

They successfully treated and saved over 7,000 lives in their clinics and more than 1,200 in the Trinity Baptist Church C19 advocacy.

Fareed/Tyson COVID-19 Treatment Protocol

HCQ 200 mg tabs #16 (HCQ = hydroxychloroquine)

Zinc sulfate 22O mg (or elemental Zinc 50 mg) # 15

Azithromycin 500 mg # 5 (or Z pack) or

Doxycycline 100 mg # 10)

Ivermectin 3 mg tabs #8

Aspirin 325 mg tabs #30

Ivermectin in the Prevention and Treatment of COVID-19

A Summary Statement By Rob Rennebohm, MD

Treatment of COVID-19 with IVM has been far more extensively and carefully studied than has treatment of COVID-19 with Paxlovid, Molnupiravir, or remdesivir.

More than 95 clinical trials (78 of which have been published in peer-reviewed journals)

o More than 2 dozen RCTs showing benefit from IVM
o Several Meta-analyses of RCTs showing benefit from IVM
o Many OCTs (observational controlled trials) showing benefit from IVM
o Many published reports of successful widespread government-sponsored IVM distribution programs (in Peru, Argentina, Paraguay, Brazil, Mexico, Honduras,

India, and the Philippines.

Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial

Nasopharyngeal clearance of SARS-CoV-2 was tested after single time application of PVP-I nasal irrigation (NI) at diluted concentrations of .4%, .5% and .6% and PVP-I nasal spray (NS) at diluted concentrations of .5% and .6%.

We observed a statistically significant proportion of nasopharyngeal clearance with all strengths of PVP-I NI and PVP-I NS compared to the corresponding controls.

The only adverse event was nasal irritation recorded in two patients each in the 0.4% and 0.6% PVP-I NI groups

Our recommendation is to use PVP-I in naopharynx (as well as oropharynx) to prevent COVID-19.

Preventive Vitamin D Supplementation and Risk for COVID-19 Infection: A Systematic Review and Meta-Analysis

The aim of this systematic review and meta-analysis is to demonstrate that preventive vitamin D supplementation can play a protective role in the incidence of COVID-19, mortality and admission to intensive care units (ICUs).Subsequent analyses were conducted by type of subject treated (patient/healthcare workers) and type of supplementation (vitamin D vs. placebo/no treatment or high dose vs. low dose). Our meta-analysis suggests a definitive and significant association between the protective role of vitamin D and COVID-19 incidence and ICU admission.

TREATMENTS FOR THOSE SUFFERING FROM LONG COVID OR VACCIne injurIES

There are starting to appear in the medical literature treatments for Long COVID and vaccine injuries. As the material is published, we will be adding it here.

Please refer to our disclaimer here

Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes

The empiric regimen can be continued for 3-12 months or more and be guided by clinical parameters:

-Nattokinase 2000 FU (100) mg orally twice a day without food

-Bromelain 500 mg orally once a day without food

-Curcumin 500 mg orally twice a day (nano, liposomal, or with piperine additive suggested)

No therapeutic claims can be made for this regimen because it has not been tested in large, prospective, double-blind, placebo controlled randomized trials. No such studies are planned or funded currently by federal or institutional sponsors. The main caveats are bleeding and allergic reactions. The regimen can be used in addition to antiplatelet and antithrombic agents, however, caution is advised with respect to monitoring bleeding risks.

McCullough Protocol Base Spike Protein Detoxification

the S1 segment accumulates in the body from SARS-CoV-2 infection and the full-length S1-S2 segment Spike is circulating and accumulating after genetic COVID-19 vaccination. Syndromes and diseases occurring as post-acute sequalae are caused by the Spike protein and the inflammation and damage it inflicts on the body.

The McCullough Protocol Base Spike Protein Detoxification is the only published method offering hope of elimination of Spike protein from the body as the root cause. It can be purchased here.

Magnolia officinalis (Magnolia Bark)

Magnolia officinalis (Magnolia Bark): Inhibiting NOX and SARS-CoV-2 Replication

This potent nutraceutical also provides Anti-Inflammatory and Anti-Cancer benefits.

Magnolia Bark shows its promise in treating SARS-CoV-2 as Honokiol is able to inhibit SARS-CoV-2 replication. So, clearly, it demonstrates an ability to treat acute COVID.

In addition to the above acute COVID benefit, Magnolia Bark may be able to treat those with Long COVID and/or Spike Protein exposure pathologies. In particular, Magnolia Bark can inhibit NOX, which the Spike Protein/SARS-CoV-2 activates.

clinical guidance for medical practitioners

IVERMECTIN

There are over 100 different studies, often ignored by critics, that demonstrate Ivermectin's efficacy. Here are ten that jump out:

S. Ahmed et al. (2020): Outcome: 85% improved symptoms (p=0.09), 76% improved viral clearance (p=0.03).	R. Chahla et al. (2021): Outcome: 95% fewer moderate/severe cases (p=0.002) and 84% fewer cases (p=0.004). No moderate/severe cases in the treatment group vs. 10 in the control group.	R. Mahmud et al. (2020): Outcome: 86% lower mortality (p=0.25), 57% lower progression (p=0.001), 94% improved recovery (p<0.0001), and 39% improved viral clearance (p=0.002).	V. Desort-Henin et al. (2023): Outcome: 96% fewer cases (p<0.0001) with pre-exposure prophylaxis.
M. Varnaseri et al. (2024): Outcome: 82% lower ventilation (p=0.02), 83% lower ICU admission (p=0.0004), 33% shorter hospitalization (p=0.001), and 28% faster recovery (p<0.0001).	A. Biber et al. (2021): Outcome: 70% lower hospitalization (p=0.34) and 62% improved viral clearance (p=0.02).	R. Chahla et al. (2021): Outcome: 87% higher hospital discharge (p=0.004)	M. Khan et al. (2020): Outcome: 87% lower mortality (p=0.02), 89% lower ICU admission (p=0.007), 83% lower progression (p=0.0004), and 87% improved recovery (p=0.02).
Z. Aref et al. (2021): Outcome: 63% improved recovery (p=0.0001) and 79% improved viral clearance (p=0.004).	A. Chowdhury et al. (2020) Outcome: 81% lower hospitalization (p=0.23), 46% improved recovery (p<0.0001), and 81% improved viral clearance (p=0.23).

ministry of health & wellness protocols

EARLY TREATMENTS FOR COVID-19

TREATMENTS FOR THOSE SUFFERING FROM LONG COVID OR VACCIne injurIES

clinical guidance for medical practitioners

IVERMECTIN

S. Ahmed et al. (2020): Outcome: 85% improved symptoms (p=0.09), 76% improved viral clearance (p=0.03).

R. Chahla et al. (2021): Outcome: 95% fewer moderate/severe cases (p=0.002) and 84% fewer cases (p=0.004). No moderate/severe cases in the treatment group vs. 10 in the control group.

R. Mahmud et al. (2020): Outcome: 86% lower mortality (p=0.25), 57% lower progression (p=0.001), 94% improved recovery (p<0.0001), and 39% improved viral clearance (p=0.002).

V. Desort-Henin et al. (2023): Outcome: 96% fewer cases (p<0.0001) with pre-exposure prophylaxis.

M. Varnaseri et al. (2024): Outcome: 82% lower ventilation (p=0.02), 83% lower ICU admission (p=0.0004), 33% shorter hospitalization (p=0.001), and 28% faster recovery (p<0.0001).

A. Biber et al. (2021): Outcome: 70% lower hospitalization (p=0.34) and 62% improved viral clearance (p=0.02).

R. Chahla et al. (2021): Outcome: 87% higher hospital discharge (p=0.004)

M. Khan et al. (2020): Outcome: 87% lower mortality (p=0.02), 89% lower ICU admission (p=0.007), 83% lower progression (p=0.0004), and 87% improved recovery (p=0.02).

Z. Aref et al. (2021): Outcome: 63% improved recovery (p=0.0001) and 79% improved viral clearance (p=0.004).

A. Chowdhury et al. (2020) Outcome: 81% lower hospitalization (p=0.23), 46% improved recovery (p<0.0001), and 81% improved viral clearance (p=0.23).